CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.

US pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...